Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca
Triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech1...
Month: October 2021
Greenrose Acquisition Corp. Sets Special Shareholder Meeting to Vote on Proposed Business Combination for October 27, 2021 at 9:00 A.M. Eastern Time
AMITYVILLE, N.Y., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Greenrose Acquisition Corp. (OTC: GNRSU, GNRS, GNRSW) (“Greenrose” or the “Company”), a...
AltruBio to Present Abstract on Checkpoint Regulator Neihulizumab as a Novel Therapy for Immunological Diseases at the B&T Cell-Mediated Autoimmune Disease Drug Development Virtual Summit
SAN FRANCISCO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated...
BioCardia Announces Participation at the A.G.P. Biotech & Specialty Pharma Conference October 13, 2021 (Virtual Conference)
SAN CARLOS, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a company focused on developing cellular and cell...
Saniona to participate in multiple upcoming virtual investor conferences
PRESS RELEASE 6 October 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that...
Radboud university medical center study sets new milestone with 90% diagnostic accuracy of lung nodules suspected of cancer using Philips technology for bronchoscopic procedures
Dr. Erik van der Heijden Radboudumc Nijmegen Lung biopsy using Philips 3D navigation - 1 Lung biopsy using Philips 3D...
Rapid Therapeutic Science Laboratories to Conduct a Shareholder Update Conference Call on Thursday, October 7, 2021
DALLAS, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Rapid Therapeutics Science Laboratories (OTC: RTSL) ("Rapid Therapeutic'' or the "Company"), a growth-oriented...
aTyr Pharma Announces Appointment of Robert W. Ashworth, PhD, as Vice President of Regulatory Affairs
SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery...
Sunshine Biopharma Files a Patent Application Covering mRNA Molecules for Treatment of Neurodegenerative Diseases
MONTREAL, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research,...
CENTOGENE and Twist Bioscience to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases
Combining Expertise to Advance Precision Medicine, While Enabling a More Efficient and Timely Diagnosis of Rare Diseases Around the WorldCAMBRIDGE,...
Aadi Bioscience to Present New Preclinical Data on nab-Sirolimus (ABI-009) at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
- Poster Presentation to go Live on October 7, 2021 at 9 a.m. ET and on Demand at the AACR-NCI-EORTC...
Arch Therapeutics to Present at the LD Micro Main Event
In-Person Presentation on October 13, 2021FRAMINGHAM, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or...
Statera Biopharma, Inc. to Participate in the A.G.P. Biotech and Specialty Pharma Conference
FORT COLLINS, Colo., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation...
Heat Biologics Appoints Paul Tebbey as Senior Vice President of Product Development and Portfolio Strategy
DURHAM, N.C., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on...
Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema
NTLA-2002 is the first single-dose genome editing therapeutic candidate designed to prevent attacks in people living with HAE to enter...
Affinia Therapeutics Appoints Carole Faig to Board of Directors
WALTHAM, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for...
Dentsply Sirona to Host Third Quarter 2021 Conference Call on November 4th
CHARLOTTE, N.C., Oct. 06, 2021 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY), announced today that the Company will be hosting an...
VitalHub Announces Multi-Year Licensing of the MCAP Patient Flow Solution to Harrogate and District NHS Foundation Trust, UK
TORONTO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) announced today that Harrogate and...
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150, a Dual-Transgene Intravitreal Gene Therapy for Patients with wet AMD
Initiation of 4D-150 Phase 1/2 clinical trial sites expected before year-endEMERYVILLE, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- 4D Molecular...
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-710, an A101 Vector-based, Aerosol-delivered Gene Therapy for the Treatment of Cystic Fibrosis Lung Disease
Initiation of 4D-710 Phase 1/2 clinical trial sites expected before year-endEMERYVILLE, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- 4D Molecular...
